NASDAQ · Drug Manufacturers - Specialty & Generic

AYTU (AYTU) Stock

$2.28 +3.23% NASDAQ: AYTU Healthcare

Valuation

MetricValue
Price$2.28
Market Cap$24.49M
P/E Ratio-1.00
P/B Ratio0.92
P/S Ratio0.31
EPS (TTM)$-2.16
52-Week High$3.07
52-Week Low$1.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-73.68%
ROA-11.29%
ROCE-42.11%
Gross Margin-12.12%
Operating Margin-12.12%
Net Margin-60.17%
Debt/Equity0.65
Current Ratio1.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$66.0M$97.0M$107.0M$65.0M$66.0M
Operating Profit$-59.0M$-110.0M$-17.0M$-2.0M$-8.0M
Net Profit$-58.0M$-109.0M$-17.0M$-16.0M$-14.0M
EPS$-69.60$-74.01$-5.11$-2.86$-2.16
Op Margin-89.7%-113.7%-15.9%-2.4%-11.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$266.0M$138.0M$138.0M$119.0M$124.0M
Total Liabilities$128.0M$93.0M$98.0M$91.0M$105.0M
Cash$50.0M$19.0M$23.0M$20.0M$31.0M
Borrowings$31.0M$18.0M$30.0M$16.0M$23.0M

Latest News

New Strong Sell Stocks for July 20th Zacks · Jul 20, 2026 New Strong Sell Stocks for July 16th Zacks · Jul 16, 2026 Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 ACCESS Newswire · Jun 1, 2026 Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 ACCESS Newswire · May 18, 2026 Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary Moby · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-26.0M$-29.0M$-5.0M$-1.0M$-2.0M
Investing Cash Flow$-3.0M$-3.0M$0$-1.0M$-6.0M
Financing Cash Flow$-6.0M$-5.0M$-4.0M$-3.0M$-6.0M
Net Cash Flow$2.0M$-31.0M$4.0M$-3.0M$11.0M
Free Cash Flow$-26.0M$-29.0M$-5.0M$-2.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield9.44%
Quick Ratio1.00
Interest Coverage-2.00
Return 1Y2.30%
Return 3Y18.72%
Return 5Y-97.38%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
ALURAllurion Technologies Inc. $4.72 -14.27% -0.08 $4.72M 0.00%
ANLAdlai Nortye Ltd. $13.26 +2.00% -8.19 $703.84M 0.00%
BFRI $1.17 -4.88% -0.90 $14.98M 0.00%
EKSOEkso Bionics Holdings, Inc. $15.90 -9.86% -2.95 $38.57M 0.00%

About AYTU

AYTU is led by CEO Joshua R. Disbrow, employs 102 people, headquartered in US, publicly traded since 2008.

AYTU stock trades at $2.28 with a market capitalization of $24.49M. The stock is valued at a price-to-earnings (P/E) ratio of -1.00, price-to-book of 0.92, price-to-sales of 0.31. Over the past 52 weeks the stock has ranged between $1.65 and $3.07, and currently trades 25.7% below its 52-week high.

On profitability, AYTU generates a return on equity (ROE) of -73.68%, return on capital employed of -42.11%, an operating margin of -12.12%, a net profit margin of -60.17%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides